- Home
- KINS vs MCRB Comparison
KINS vs MCRB Comparison
Compare KINS & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KINS
- MCRB
- Stock Information
- Founded
- KINS 1886
- MCRB 2010
- Country
- KINS United States
- MCRB United States
- Employees
- KINS N/A
- MCRB N/A
- Industry
- KINS Property-Casualty Insurers
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- KINS Finance
- MCRB Health Care
- Exchange
- KINS Nasdaq
- MCRB Nasdaq
- Market Cap
- KINS 189.6M
- MCRB 165.3M
- IPO Year
- KINS N/A
- MCRB 2015
- Fundamental
- Price
- KINS $13.73
- MCRB $18.03
- Analyst Decision
- KINS
- MCRB Hold
- Analyst Count
- KINS 0
- MCRB 4
- Target Price
- KINS N/A
- MCRB $73.67
- AVG Volume (30 Days)
- KINS 149.6K
- MCRB 245.0K
- Earning Date
- KINS 10-28-2025
- MCRB 11-12-2025
- Dividend Yield
- KINS 1.46%
- MCRB N/A
- EPS Growth
- KINS 325.10
- MCRB N/A
- EPS
- KINS 2.04
- MCRB 10.22
- Revenue
- KINS $183,702,376.00
- MCRB N/A
- Revenue This Year
- KINS $41.35
- MCRB N/A
- Revenue Next Year
- KINS $12.33
- MCRB N/A
- P/E Ratio
- KINS $6.70
- MCRB $1.76
- Revenue Growth
- KINS 28.36
- MCRB N/A
- 52 Week Low
- KINS $8.36
- MCRB $6.53
- 52 Week High
- KINS $22.40
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- KINS 46.67
- MCRB 52.55
- Support Level
- KINS $13.38
- MCRB $14.22
- Resistance Level
- KINS $13.92
- MCRB $24.67
- Average True Range (ATR)
- KINS 0.47
- MCRB 2.08
- MACD
- KINS 0.08
- MCRB -0.38
- Stochastic Oscillator
- KINS 43.28
- MCRB 36.48
About KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.